Mark D Tyson1, Erik P Castle2. 1. Department of Urology, Mayo Clinic Hospital, Phoenix, AZ. 2. Department of Urology, Mayo Clinic Hospital, Phoenix, AZ. Electronic address: castle.erik@mayo.edu.
Abstract
OBJECTIVE: To examine whether racial disparities in survival exist among black, Hispanic, and Asian patients compared with white patients with clinically localized prostate cancer (CLPC) after adjustment for the effects of treatment. PATIENTS AND METHODS: We performed a retrospective cohort study of patients with CLPC diagnosed from January 1, 1995, through December 31, 2003, as documented in the Surveillance, Epidemiology, and End Results registry. Treatment-stratified, risk-adjusted Cox proportional hazards models were constructed. RESULTS: During the study period, CLPC was diagnosed in 294,160 patients. Of these patients, 123,850 (42.1%) underwent surgery and 101,627 (34.5%) underwent radiotherapy, whereas 68,683 (23.3%) received no treatment. Overall 5-year and 10-year survival rates for Asians (85.6% and 67.6%, respectively), Hispanics (85.9% and 69.0%, respectively), and whites (83.9% and 65.7%, respectively) were higher than for blacks (81.5% and 61.7%, respectively) (P<.001). Prostate cancer-specific survival also varied significantly by race (P<.001). A risk-adjusted model stratified by primary treatment modality revealed that blacks had worse overall survival than whites (hazard ratio, 1.37; 95% CI, 1.33-1.41; P<.001), whereas Asians had better survival compared with whites (hazard ratio, 0.79; 95% CI, 0.76-0.83; P<.001). After the effects of treatment were accounted for, Hispanics had similar overall survival compared with whites (hazard ratio, 0.97; 95% CI, 0.94-1.01; P=.10). CONCLUSION: Blacks with CLPC have poorer survival than whites, whereas Asians have better survival, even after risk adjustment and stratification by treatment. These data may be relevant to US regions with large underserved populations that have limited access to health care.
OBJECTIVE: To examine whether racial disparities in survival exist among black, Hispanic, and Asian patients compared with white patients with clinically localized prostate cancer (CLPC) after adjustment for the effects of treatment. PATIENTS AND METHODS: We performed a retrospective cohort study of patients with CLPC diagnosed from January 1, 1995, through December 31, 2003, as documented in the Surveillance, Epidemiology, and End Results registry. Treatment-stratified, risk-adjusted Cox proportional hazards models were constructed. RESULTS: During the study period, CLPC was diagnosed in 294,160 patients. Of these patients, 123,850 (42.1%) underwent surgery and 101,627 (34.5%) underwent radiotherapy, whereas 68,683 (23.3%) received no treatment. Overall 5-year and 10-year survival rates for Asians (85.6% and 67.6%, respectively), Hispanics (85.9% and 69.0%, respectively), and whites (83.9% and 65.7%, respectively) were higher than for blacks (81.5% and 61.7%, respectively) (P<.001). Prostate cancer-specific survival also varied significantly by race (P<.001). A risk-adjusted model stratified by primary treatment modality revealed that blacks had worse overall survival than whites (hazard ratio, 1.37; 95% CI, 1.33-1.41; P<.001), whereas Asians had better survival compared with whites (hazard ratio, 0.79; 95% CI, 0.76-0.83; P<.001). After the effects of treatment were accounted for, Hispanics had similar overall survival compared with whites (hazard ratio, 0.97; 95% CI, 0.94-1.01; P=.10). CONCLUSION: Blacks with CLPC have poorer survival than whites, whereas Asians have better survival, even after risk adjustment and stratification by treatment. These data may be relevant to US regions with large underserved populations that have limited access to health care.
Authors: Susan Halabi; Sandipan Dutta; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Ian M Thompson; Kim N Chi; John C Araujo; Christopher Logothetis; David I Quinn; Karim Fizazi; Michael J Morris; Mario A Eisenberger; Daniel J George; Johann S De Bono; Celestia S Higano; Ian F Tannock; Eric J Small; William Kevin Kelly Journal: J Clin Oncol Date: 2018-12-21 Impact factor: 44.544
Authors: Helen Y Hougen; Oleksii A Iakymenko; Sanoj Punnen; Chad R Ritch; Bruno Nahar; Dipen J Parekh; Oleksandr N Kryvenko; Mark L Gonzalgo Journal: World J Urol Date: 2022-06-10 Impact factor: 3.661
Authors: Motolani E Ogunsanya; Carolyn M Brown; Folakemi T Odedina; Jamie C Barner; Brittany Corbell; Taiwo B Adedipe Journal: Am J Mens Health Date: 2016-07-08
Authors: Marianne Schmid; Christian P Meyer; Gally Reznor; Toni K Choueiri; Julian Hanske; Jesse D Sammon; Firas Abdollah; Felix K H Chun; Adam S Kibel; Reginald D Tucker-Seeley; Philip W Kantoff; Stuart R Lipsitz; Mani Menon; Paul L Nguyen; Quoc-Dien Trinh Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Ewan K Cobran; Ronald C Chen; Robert Overman; Anne-Marie Meyer; Tzy-Mey Kuo; Jonathon O'Brien; Til Sturmer; Nathan C Sheets; Gregg H Goldin; Dolly C Penn; Paul A Godley; William R Carpenter Journal: Am J Mens Health Date: 2015-02-05
Authors: Mindy C DeRouen; Clayton W Schupp; Jocelyn Koo; Juan Yang; Andrew Hertz; Salma Shariff-Marco; Myles Cockburn; David O Nelson; Sue A Ingles; Esther M John; Scarlett L Gomez Journal: Cancer Epidemiol Date: 2018-01-09 Impact factor: 2.890